2 results
Categories
Human Remove Human filter
Medicine type
Generic Remove Generic filter
Biosimilar Remove Biosimilar filter
Accelerated assessment Remove Accelerated assessment filter
Orphan medicine Remove Orphan medicine filter
Exceptional circumstances Remove Exceptional circumstances filter
Medicine
Orphan designations Remove Orphan designations filter
Withdrawn applications Remove Withdrawn applications filter
Referrals Remove Referrals filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
Variation Remove Variation filter
-
List item
Referral: Zynteglo
betibeglogene autotemcel, associated names: Zynteglo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 22/07/2021, EC decision date: 16/09/2021, Last updated: 11/10/2021 -
List item
Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)
daclatasvir, dasabuvir, sofosbuvir, ledipasvir, simeprevir, ombitasvir, paritaprevir, ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017